“The Evolution of Lymphangioleiomyomatosis (LAM) Management: From Hormonal Manipulation to Targeted Inhibition of the mammalian target of rapamycin (mTOR) Pathway” (2025) Research, Society and Development, 14(4), p. e4614448656. doi:10.33448/rsd-v14i4.48656.